European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
HSBC Cuts 10% of U.S. Debt Capital Markets Team Amid Ongoing Business Revamp 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Moncler Shares Surge on Strong Q4 Revenue Growth and Robust China Demand 
Nvidia Nears $30 Billion Investment in OpenAI, Replacing Previous $100 Billion AI Partnership 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Alibaba, Baidu, BYD Shares Slide After Pentagon Military List Update 
Nvidia Earnings Preview: AI Growth Outlook Remains Strong Beyond 2026 
PacifiCorp to Pay $575 Million in Wildfire Settlement With U.S. Government 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
JPMorgan Closes Trump Accounts as $5 Billion Lawsuit Moves to New York 
Amazon Surpasses Walmart in Annual Revenue, Signaling a New Era in Retail Competition 
SAN DIEGO, May 08, 2018 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its first quarter financial results on Monday, May 14, 2018 before the open of the U.S. financial markets. Company management will host a conference call and webcast on Monday, May 14, 2018 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss the results and provide a corporate update.
Interested parties may access the call by dialing toll-free (844) 358-9116 from the US or (209) 905-5951 internationally and using conference ID 8255679.
The press release and links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts. An audio replay will be available for at least 90 days following the event.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and development of innovative medicines using its knowledge of newly discovered pathways in immunology effected by extracellular tRNA synthetases. To date, aTyr has generated innovative and unique development programs based on its knowledge of extracellular histidyl-tRNA synthetase (HARS), known as the Resokine pathway. aTyr’s clinical stage ATYR1923 candidate is an agonist of the Resokine pathway designed to temper immune engagement in interstitial lung diseases. aTyr’s preclinical research stage ORCA program, targets a novel, proprietary immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 250 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein compositions derived from tRNA synthetase genes. For more information, please visit http://www.atyrpharma.com.
IMMEDIATE RELEASE
Contact:
Mark Johnson
Sr. Director, Investor Relations
[email protected]
858-223-1163
